Neuren Pharmaceuticals achieves breakthrough in Pitt Hopkins syndrome treatment
Neuren Pharmaceuticals (ASX: NEU) has announced promising top-line results from its Phase 2 clinical trial of NNZ-2591, aimed at treating children with Pitt Hopkins syndrome ... Read More
Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases, today disclosed promising topline results from its ... Read More
EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU ... Read More
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial, OMS-104, aimed at evaluating the combination of ... Read More